C22.9: Malignant neoplasm of liver, not specified as primary or secondary

Risk adjustment

C22.9 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:

• HCC 20 Lung and Other Severe Cancers1.136 RAF

Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.

Medicare coverage

C22.9 is named in 63 Medicare coverage policies: 63 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.

• A52370Billing and Coding: Bevacizumab and biosimilars
• A52479Oral Anticancer Drugs - Policy Article
• A52480Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article
• A52986Billing and Coding: Biomarkers for Oncology